CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
OPERATING EXPENSES
Research and development	$ 6,019,759	$ 4,485,772
Financing costs (Notes 7 and 8)	4,325	1,181
General and administration	3,062,170	2,208,917
Total operating expenses	(9,086,254)	(6,695,870)
Foreign exchange	13,169	7,196
Interest income	74,584	35,691
Derivative liability gain (Note 8)	(99,318)	89,130
Loss for the period before taxes	(9,097,819)	(6,563,853)
Income tax recovery (expense)	(100)	35,149
Loss and comprehensive loss for the period	$ (9,097,919)	$ (6,528,704)
Basic and diluted loss per common share	$ (0.21)	$ (0.20)
Weighted average number of common shares outstanding - basic and diluted	43,989,773	33,343,488